Evidence map›Paper›PMID 32937269›Full record

ArticleBiomaterials2020

Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients.

Abraham R Tzafriri, Benny Muraj, Fernando Garcia-Polite, Antonio G Salazar-Martín, Peter Markham, Brett Zani, Anna Spognardi, Mazen Albaghdadi, Steve Alston, Elazer R Edelman

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Endovascular Drug Delivery.Life (Basel, Switzerland) · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. The factors influencing the efficiency of drug-coated balloons.Frontiers in cardiovascular medicine · 2022
    Review
  17. Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021
    Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Abraham R TzafririCBSET Inc, 500 Shire Way, Lexington, MA, USA. Electronic address: rtzafriri@cbset.org.
Benny MurajCBSET Inc, 500 Shire Way, Lexington, MA, USA.
Fernando Garcia-PoliteCBSET Inc, 500 Shire Way, Lexington, MA, USA.
Antonio G Salazar-MartínCBSET Inc, 500 Shire Way, Lexington, MA, USA.
Peter MarkhamCBSET Inc, 500 Shire Way, Lexington, MA, USA.
Brett ZaniCBSET Inc, 500 Shire Way, Lexington, MA, USA.
Anna SpognardiCBSET Inc, 500 Shire Way, Lexington, MA, USA.
Mazen AlbaghdadiCBSET Inc, 500 Shire Way, Lexington, MA, USA; Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Steve AlstonW.L. Gore & Associates, 1505 N Fourth St, Flagstaff, AZ, 86004, USA.
Elazer R EdelmanIMES, MIT, 77 Massachusetts Avenue Cambridge, MA, USA; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
IIT@MIT · USMassachusetts General Hospital · USW. L. Gore & Associates (United States) · US

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS R01 GM049039
6 · The paper itself

Abstract

Paclitaxel coated balloon catheters (PCB) were developed as a polymer-free non-implantable alternative to drug eluting stents, delivering similar drug payloads in a matter of minutes. While PCB have shown efficacy in treating peripheral arterial disease in certain patient groups, restenosis rates remain high and there is no class effect. To help further optimize these devices, we developed a scanning electron microscopy (SEM) imaging technique and computational modeling approach that provide insights into the coating micromorphology dependence of in vivo drug transfer and retention. PCBs coated with amorphous/flaky or microneedle coatings were inflated for 60 sec in porcine femoral arteries. Animals were euthanized at 0.5, 24 and 72 h and treated arteries processed for SEM to image endoluminal coating distribution followed by paclitaxel quantification by mass spectrometry (MS). Endoluminal surfaces exhibited sparse coating patches at 0.5 h, predominantly protruding (13.71 vs 0.59%, P < 0.001), with similar micro-morphologies to nominal PCB surfaces. Microneedle coating covered a 1.5-fold endoluminal area (16.1 vs 10.7%, P = 0.0035) owing to higher proximal and distal delivery, and achieved 1.5-fold tissue concentrations by MS (1933 vs 1298 μg/g, P = 0.1745) compared to amorphous/flaky coating. Acute longitudinal coating distribution tracked computationally predicted microindentation pressure gradients (r = 0.9, P < 0.001), with superior transfer of the microneedle coatings attributed to their amplification of angioplasty contact pressures. By 24 h, paclitaxel concentration and coated tissue areas both declined by >93% even as nonprotruding coating levels were stable between 0.5 and 72 h, and 2.7-fold higher for microneedle vs flaky coating (0.64 vs 0.24%, P = 0.0195). Tissue retained paclitaxel concentrations at 24-72 h trended 1.7-fold higher post treatment with microneedle coating compared to the amorphous/flaky coating (69.9 vs 39.9 μg/g, P = 0.066). Thus, balloon based drug delivery is critically dependent on coating micromorphologies, with superior performance exhibited by micromorphologies that amplify angioplasty pressures.

Indexed as

Drug-Eluting StentsPaclitaxelAngioplastyAnimalsCoated Materials, BiocompatibleExcipientsFemoral ArteryHumansSwineTreatment OutcomeCoated Materials, BiocompatibleExcipientsPaclitaxelCoronary artery diseaseDrug coated balloonsPaclitaxelPeripheral artery disease

Identifiers

PMID32937269
PMCPMC7530113
OpenAlexW3064037380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.